IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Tower Bridge Advisors

Tower Bridge Advisors lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 74,055 shares of the medical research company’s stock after selling 1,454 shares during the quarter. IQVIA makes up about 1.5% of Tower Bridge Advisors’ holdings, making the stock its 12th biggest position. Tower Bridge Advisors’ holdings in IQVIA were worth $14,553,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP purchased a new position in shares of IQVIA during the third quarter worth approximately $27,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the fourth quarter worth approximately $33,000. Avior Wealth Management LLC grew its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the last quarter. Assetmark Inc. grew its position in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in shares of IQVIA during the third quarter worth approximately $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on IQV shares. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Finally, TD Cowen lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Price Performance

IQVIA stock opened at $188.89 on Friday. The company has a market cap of $33.26 billion, a P/E ratio of 25.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a one year low of $184.66 and a one year high of $261.73. The business has a fifty day moving average of $199.13 and a two-hundred day moving average of $214.96.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.